Policy Research Journal
ISSN (E): 3006-7030 ISSN (P) : 3006-7022 Volume 3, Issue 10, 2025

ARTIFICIAL INTELLIGENCE FOR AUTOMATED DETECTION AND DIAGNOSIS OF BREAST CANCER IN MAMMOGRAPHIC IMAGING

Muhammad Asif Riaz[1], Hira Saleem[*2], Naeem Aslam[3], Feza Iftikhar[4], Huma Kashaf Chughtai[5]

[1,*2,3,4,5] *Department of Computer Science, NFC Institute of Engineering and Technology, Multan, Pakistan*

[1]asif05010@gmail.com, [*2]hira.saleem@nfciet.edu.pk, [3]naeem.aslam@nfciet.edu.pk,
[4]fezaiftikhar9@gmail.com, [5]humakashafchughtai@gmail.com

DOI: https://doi.org/10.5281/zenodo.17256684

Keywords
Artificial Intelligence; Breast Cancer Detection; Mammography; Deep Learning; Transfer Learning; Residual Networks; Invasive Ductal Carcinoma; Medical Imaging

Article History
Received: 12 August 2025
Accepted: 22 September 2025
Published: 03 October 2025

Corresponding Author: *
Hira Saleem

Abstract
Breast cancer remains one of the most prevalent malignancies worldwide and a leading cause of mortality among women. Early detection is critical for improving survival outcomes, yet traditional mammography interpretation faces challenges such as inter-observer variability, dense breast tissues, and high false-positive rates. Recent advances in artificial intelligence (AI) and deep learning have enabled automated detection systems with significant diagnostic potential. This paper proposes TransResCNN, a hybrid framework integrating transfer learning with residual convolutional neural networks (ResNet) to improve automated breast cancer detection in mammographic images. The model leverages pre-trained ResNet weights for enhanced feature extraction, residual connections to mitigate vanishing gradients, and data augmentation strategies to address class imbalance. Evaluated on publicly available histopathology image datasets, TransResCNN achieved 90.76% accuracy and 93.56% F1-score, outperforming baseline CNN models and demonstrating robust generalization. Comparative analysis against state-of-the-art approaches confirms the superiority of the proposed framework. These results highlight the potential of TransResCNN to augment radiologists' decision-making, reduce diagnostic errors, and support clinical breast cancer screening at scale.

INTRODUCTION

Breast cancer is one of the most common complications within the public health system because it is the most commonly diagnosed form of cancer in women of all ages throughout the world and one of the most common causes of death related to cancer. According to the estimates provided by the World Health Organization (WHO), 2.3 million cases and 685,000 deaths of cancer of the breast were experienced in the world in 2020. Due to the rising life expectancy, lifestyles, and inaccessibility to screening in low-and-middle-income countries, the effects of the disease are likely to keep escalating. Other developed nations have implemented countrywide screening programs that, although subject to early diagnosis and increased survival, resource limited settings continue to find it difficult to detect and intervene in a sufficient manner. Mammography remains the normal of screening breast cancer because it enables radiologists to identify the existence of abnormalities during the initial phases. However, the process of diagnosis has a limit[1], [2]. Mammogram also requires professional interpretation and other factors such as dense breast tissue; delicacy of lesions and radiologist burnout can also affect the accuracy. False-positives will lead to the unnecessary biopsies and anxiety, whereas false negatives can lead to the delayed treatment and worsen the results. Subsequently, there is a dire need of automated, more accurate and reproducible methods to support radiologists in the diagnosis of breast cancer.

Artificial intelligence (AI) and deep learning (DL) is a new disruptive technology in the field of medical imaging. Over the past 10 years, convolutional neural networks (CNNs) have proven to be highly effective in image classification, image segmentation, and image detection challenges in different domains, including oncology. AI models have the ability to enhance interpretation discrepancies in breast cancer screening, handle large amounts screening data successfully, and assist in locating small patterns that would have otherwise been missed to the human eye. Despite these strengths, there are many opportunities that are barriers to the clinical implementation of AI systems[3].

Current Challenges in Breast Cancer Detection

The current problems of the breast cancer screening are complicated and have extensive consequences on the diagnosis and survival of the patients worldwide. Despite breast cancer being the most prevalent type of cancer in women worldwide, with millions of new cases per year, there are greater barriers to early cancer detection programs, especially in low- and middle-income nations (LMICs). Poor infrastructure, not reaching well-structured screening services and socioeconomic disparities contribute to large variations in survival rates often not exceeding 40 in resource-poor regions versus over 90 in rich nations. The gold standard of breast cancer screening, mammography, is linked to various limitations including reduced accuracy in dense breast tissues, inter-reader variation, and high levels of false-positives; leading to unnecessary biopsies and anxiety of patient[4], [5]. The malignant lesions are obscured by the fatty breast tissue common among young women thereby making it very hard to spot and hence thus false negative thereby delaying treatment thereby worsening the prognosis. In addition, mammogram interpretation is labor intensive activity and it depends on the competence of the day-to-day radiologists and the number of screening tests per day continuously stretches the health care system of most countries of the world. These issues underscore the fact that there are indeed certain screening policies that are absolutely required in the resolution of whether there exist resource bases and risks on the population level, as backed by the reports of the international organizations of health institutions that are interested in adopting scaled, equitable policies in breast cancer screening all over the world[6], [7].

When artificial intelligence (AI) is put in place in detecting breast cancer, some of the solutions to the problems are very promising but hard to win unless one can work around the situation. Both AI-based algorithms and the ones relying on deep learning, in particular, hold much promise in the domain of the automation of image interpretation, reducing variability and improving sensitivity in cases of subtle lesions detected. Nevertheless, AI cannot be applied to the clinical mammography without some operational and ethical issues. The results of the performance in the comparison of heterogeneous populations and the imaging device are non-even, and it raises a question of the generalizability and equality of AI-based diagnostics. The absence of transparency in algorithmic decision-making is frequently brought up as a hindrance to healthcare providers due to so-called black box problem, which stands in the way of trust and clinical uptake. The easy integration with the already established hospital information systems and workflow is also logistically and technically challenging[8], [9]. Regulatory control and ethical issues around patient data privacy, algorithm bias and legal responsibility are also complex factors affecting the use of AI by many patients. Despite over twenty AI applications to breast imaging that have been approved by Food and Drug Administration (FDA), there is low adoption due to these complicated obstacles. To reap the full benefits of AI, in terms of improving the capacity in radiologists, as well as in the early detection of breast cancer, well-implemented structures that consider these technical, ethical and systemic concerns are required[10].

New technologies that may serve as a complement to the traditional mammography, such as ultrasound elastography or MRI, have novel diagnostic properties, yet introduce new concerns regarding standardization, availability, and cost. Elastography U-Mode is an ultrasound mode method, employed to measure the hardness of tissue and, hence, detect benign and malignant lesions, but has experienced significant developments as shear wave elastography and quantitative strain imaging. The techniques increase sensitivity of early-stage tumors and reduce false positives in dense tissues prevalent in younger women and women of some ethnicities. However, it is not that commonly practiced because equipment is expensive, and because of affiliation with the operator and lack of standardized protocols capable of ensuring the ability to replicate the findings across different clinical settings[11]. The possibility of linking AI with the ultrasound imaging workflow to characterize lesions and detect patterns automatically requires a multifold clinical validation and training of healthcare providers. The AI-assisted breast MRI has other issues because fluctuations in data and lack of data and complex imaging regimes demand a large dataset and standardization to simplify the execution of the algorithms. The answer to these is to take multidisciplinary action to develop quality assurance criteria on a universal scale, to make more high-quality imaging services available, and to fairly distribute AI-driven diagnostic services, especially in under-resourced environments. These contradictory clinical, technological and social barriers should be broken to be able to provide the correct, effective and available diagnostics all over the world so that breast cancer can be prevented and treated as soon as possible.

Literature Review

The emerging technologies have improved the pace at which breast cancer is detected but the science has many problems, which are prompting new research. Breast cancer has been the most diagnosed cancer in all the parts of the globe and the highest cause of mortality among women with the reported rate of more than 2.3 million new cases of breast cancer each year. There is agreement that screening is one of the most significant determinants of survival and that equal access and technology is restricting its potential. The gold standard screening mode of breast cancer is mammography which has been found to have a limitation in the diagnosis of breast cancer due to factors like the presence of dense breast tissue that can obscure the tumor and give a false negative result. Analyses done recently have verified that about 20 percent of breast cancer cannot be detected by mammogram in the breasts of women who have fibroglandular dense breast that is common in younger women and some ethnic group. Such a limitation includes additional screening procedures such as ultrasound and MRI that are costly and inaccessible particularly in the low-resource states. In addition, the traditional process of imaging interpretation is subjective to the highest expertise level in the minds of the radiologist and it is likely to have inter-observer effects and this affects diagnostic consistency[12], [13]. The complexities of the clinical workflow are also well explained in the literature where the (increasing) work loads of the screening processes flood the radiology departments thereby predisposing the radiological staff to commit mistakes associated with fatigue. These are the applied and technical problems, and the investigators have been forced to consider using the supplementary diagnostic adjuncts and algorithmic interventions not only to increase sensitivity and specificity, but also to make them cost-effective and less restrictive[14], [15].

Machine learning and artificial intelligence (AI) already represent radical technologies in the sphere of breast cancer diagnostics and can be used to address a range of typical challenges that suggest automated image processing and predictive models. Recent methodological reviews dwell on the fact that AI model, and neural networks in particular, are more sensitive and specific than the traditional human reading modalities in reading mammograms. Better performance is also achieved through transfer learning and hybrid nets that exploit the pre-trained weights and synthesis of other techniques in neural network, such as residual learning, to avoid vanishing gradient issues in highly-deep networks. They have been found to decrease the false positives, a massive clinical issue that has been causing unnecessary biopsies and patient-fear and high-recall of cancer. Besides these beneficial outcomes, there are some severe barriers to clinical adoption of AI tools[16], [17]. The reproducibility and generalizability of the findings to other populations and imaging devices are quite restricted since most AI models are currently being trained on significantly homogeneous data that fail to capture the heterogeneity of the real world. This may cause the implementation performance to decline in other health care settings. Some barriers to clinician trust and regulatory approvals include ethical and legal issues, such as data privacy, an algorithmic bias, and the black box nature of deep learning models. In addition to this, the technical difficulty in incorporating AI into the current processes, including picture archiving and communication systems (PACS) to electronic health records (EHR), is another layer to the logistical strains of AI implementation. It must be available, comprehensible and must possess user interfaces to be accepted. Governance and ethical AI implementation frameworks based on the models of the implementation sciences like Consolidated Framework of Implementation Research (CFIR) are being given more attention to address such gaps between innovation and practice[18], [19].

It is also revealed in the literature that more emphasis is given to the implementation of non-invasive biomarker-based detection strategies that can be applied to complement, or even outperform more common radiological strategies and imaging and AI. Molecular and liquid biopsy is on the increase as it can identify tumor-secreting substances, namely circulating tumor cells (CTCs), cell-free DNA (cfDNA) and microRNAs in the body fluids. These biomarkers hold a bright future in early diagnosis of this cancer as the molecular signatures that are linked to the cancer are detected before the tumors emerge. They have developed some biosensor technologies based on optical and electrochemical and piezoelectric detection truths to increase the sensitivity and specificity of detection in these molecular signs. Intense research work on wearable biosensors and smart biomedical devices is underway to offer real time and easily accessible monitoring. Nevertheless, they are not ready as a clinically useful tool routinely used in the face of such a problem of biomarker heterogeneity, assay-protocol and high-scale clinical validation. The literature suggests the combination of the information about the biomarkers with the imaging and AI analytics, which is required to produce multimodal diagnostic models, which might yield more accurate results and risk stratification. Its future includes the harmonization of datasets, the correct regulation of imbalance of classes and implementation of improved algorithms to filter out the impact of noise and missing data in the biomarkers-based diagnostics[20].

Developing processes are also recent technological processes in breast imaging, which are ultrasound elastography and magnetic resonance imaging (MRI). The ultrasound elastography aids in the characterization of the hardness of tissues where benign lesions are distinguished with malignant lesions with a greater degree of specificity particularly among the dense breast tissue population[21], [22]. The literature reviews facilitate the description of the new developments in the shear wave elastography and strain imaging modalities that offer quantitative maps of stiffness, which, in combination with pattern recognition through AI, can increase the validity of the diagnostics. However, this has been attributed to some shortfalls such as dependency on the operator, absence of standard acquisition protocols, and high cost. Breast MRI and contrast-enhanced MRI in particular can be more sensitive to the disease at the first stages, however, they are not as common across the globe because of the infrastructural requirements and expenses. The most recent articles concern shorter MRI scans and AI-based lesion segmentation to transform breast MRI scans into a more viable screening method. Integration of the imaging modalities through multiparametric AI models is among the current research directions in which it would be implemented to exploit the complementary characteristics of mammography, ultrasound and MRI functions. Nevertheless, the lack of dataset homogeneity, challenges of cooperation between various institutions, and standardization of imaging parameters is a major obstacle. Such issues are being addressed, most recently, using federated learning, domain adaptation, and consensus-related rules[23].

It also has been demonstrated in clinical implementation studies that complex breast cancer detection technologies may become, in both practical and workflow integration terms.

Radiologist, clinician and patient acceptance of the technology is the key to success as it will be a source of confidence to explainability of the algorithms and consistency of the performance indicators. It has been demonstrated that the educational programs and continuous advancement of AI technologies and the clinical audience can enhance the usability and dependability of the results[24]. Healthcare disparities are more of a priority, and should be considered since, technology-based advances will only worsen the already existing disparities. By the way, marginalized people and LMICs are unlikely to have access to the latest screening possibilities and well-heavy digital technologies to implement AI[25]. The idea of a bespoke technology construction in accordance to the resources at hand and the cultural backgrounds is perpetuated in literature. The economic analyses proceed to present a cost-benefit analysis, which is critical in the decision-making process of health policy that is both centered on scalable and sustainable solutions. It is likewise a proposal in the formats of the public health that comprises the blend of the danger evaluation techniques that encompass the genetic, environmental and the lifestyle variables to personalize the screening periods[9]. Meanwhile, ethical regulations also aid in controlling data on equal standing, and they aim to ensure that algorithms are not discriminatory, and patient confidentiality is not to suffer, and they also allow innovation in breast cancer detection[26].

Lastly, the trends observed in the future researches show the movement towards precision oncology and longitudinal monitoring through identifying and forecasting the reaction to treatment and prognosis. With the assistance of high-advanced AI algorithms, which are trained on longitudinal imaging and clinical data, the forecast of tumor development, the creation of individual regimens, and the evaluation of the progress of the therapy in real time are possible. The emerging multimodal imaging, genomics and proteomics data is underpinned by these efforts, with highly sophisticated data fusion methods and interpretability being required. Grad-CAM and SHAP are explainable artificial intelligence (XAI) algorithms that are gaining importance to explain the decision patterns to enhance clinical trust. Furthermore, smaller AI systems that may be deployed on edge machines and other low resource conditions are an important area of useful research, which permits equity in health in the world. The regulative science is developing in accordance with the recent tendencies, attempting to balance the requirements, on the one hand, to promptly certify the promising technologies and, on the other hand, to the great extent of safety and efficiency[27]. The application of collaborative consortia between industry, government agencies and academia would be the most imperative in the translation of research into clinic. In general, the recent literature is a dynamic and interdisciplinary approach to fill gaps that exist in the field of breast cancer detection with the intention of developing patient-centric, accessible, and reliable solutions on a global scale.

Methodology

Dataset Description

The paper will use the IDC breast histopathology dataset that contains digitized mammographic images that are identified as invasive ductal carcinoma (IDC) positive or invasive ductal carcinoma (IDC) negative. The dataset consists of approximately 277,524 image patches which were cut out of 162 whole-slide images that had been collected at the University of South Carolina. The patches are 50 50 pixels, and they are identified with the presence of IDC. The data is partitioned into training (70), validation (15) and testing (15) data subsets to ensure successful testing. This kind of separation minimizes the effects of overfitting and ensures that the model is tested on unknown data.

Data Preprocessing and Augmentation

The preprocessing and data augmentation steps are an important component of the proposed TransResCNN model performance and robustness. Firstly, the IDC breast histopathology images, retrieved as 50 x 50-pixel patches are pre-processed initially to homogenize the input dimensions and remove noise that could otherwise pose a barrier to extraction of features. Image normalization processes are employed to normalize pixel value ranges to ensure the training dynamics are always the same. As the proportion of negative patches in the dataset represented by the IDC percentage is enormous in contrast to the positive cases percentage, data augmentation techniques are commonly employed to address this imbalance of classes and reduce overfitting. S. rotation Horizontal and vertical flipping, scaling, contrast adjustment These are a group of augmentation operations that artificially improve the variety and representativeness of the training set. These modifications enable the model to gain the property of invariance which increases its generalization to out of sight test data. These augmentations also recapitulate the natural scanning variations in imaging conditions and tissue appearance that is particularly critical to histopathological data. This is an augmented dataset which is beneficial during the combination of transfer learning and a residual convolutional architecture since it can efficiently attain powerful features. In addition, augmentation and preprocessing pipeline is useful in maximizing the optimal classification measures, such as accuracy, precision, recall, and F1-score, as demonstrated in our results. Overall, the aspects of imbalance and variability of the dataset are resolved with detailed preprocessing and deliberate data augmentation, which is why the TransResCNN model can be demonstrated as a more successful in recognizing breast cancer on the IDC histopathology dataset.

Proposed Model: TransResCNN

The proposed model is a novel hybrid deep learning model, TransResCNN, that is specifically trained to identify and diagnose invasive ductal carcinoma (IDC) in mammographic images. It tactically integrates transfer learning with residual convolutional neural networks (ResNet) to capitalize on the benefits of both methods by leveraging the ability of both methods to exploit pre-trained weights on large-scale image data; and by preventing the issue of vanishing gradient common in deep networks, which enables the model to be more efficient and deeper. TransResCNN uses a properly trained series of convolutional networks which bore hierarchical and discriminative characteristics on histopathological image patches. It can use this design to identify minute textual and morphological variation, which is significant in differentiating IDC-positive and IDC-negative patches. Another benefit of the hybrid framework is the great data augmentation and preprocessing, which introduces the diversity of the training data and balances the classes. Adam optimizer hyperparameters are optimized to achieve maximum high classification performance of the model and the early termination strategies prevent overfitting. With much comparison through accuracy, precision, recall, F1-score, and ROC-AUC, TransResCNN outperforms baseline CNN architectures (such as VGG16, DenseNet, and InceptionNet) and even some state-of-the-art models and could be better balanced in terms of sensitivity and specificity to be usable in clinical practice. The higher transfer learning and residual network in TransResCNN allow the algorithm to effectively generalize on unseen data, which can make it a promising AI tool to aid radiologists in early detection of breast cancer and reduction of diagnostic errors. This is a significant methodological advancement in the automated image analyzers of mammography, which maximizes predictive accuracy, model strength and clinical usability in the AI studies of breast cancer.

The Figure 1 visually explains the step-wise process followed in the research to accomplish automated detection and diagnosis of breast cancer by assistance of the TransResCNN model. It begins with the input of the IDC breast histopathology dataset, and subsequently the data preprocessing to strip the images in order to analyze them. This dataset can then be split into training, validation and testing groups to ensure an impartial model testing. Features are then extracted using a pre-trained ResNet, to exploit transfer learning and offer the efficient and rich hierarchically representation of the image data. The extracted features are fed to the residual convolutional neural network framework that also integrates the residual connectivity to successfully train more layers and mitigate the gradient vanishing issues. To prevent overfitting, the model is optimized using optimization algorithms and performance optimization methods such as early stopping. The next stage of the model evaluation, after training, is a quantitative assessment of the performance based on such metrics as accuracy, precision, recall, and F1-score. The results are contrasted and compared with a baseline CNN with the emphasis on the efficacy of the predictive power and the generalization of TransResCNN. Finally, the figure identifies the implementation potential on clinical basis and this is where the practical application of the approach in real breast cancer screening procedures is identified. This flowchart is a brief explanation of the integrated technical and assistive components that may be observed to propel the whole research methodology.



Figure 1: Methodology flow diagram

Results and Discussion

The dataset was divided into 70% training, 15% validation, and 15% testing sets. Performance was evaluated using accuracy, precision, recall, F1-score, and ROC-AUC.

The confusion matrix of TransResCNN model on invasive ductal carcinoma (IDC) test data is depicted in Figure 2. The matrix gives significant data about the classification efficacy of the model involving true positives (TP), false negatives (FN), the false positives (FP), and the true negatives (TN). Specifically, the model identified 5,468 IDC-positive patches (TP), and falsely identified 512 positive cases (FN) as negative. This relatively low false negative rate is very relevant in clinical practice as it means that most of the malignant cases were detected and therefore it would reduce the chances of missing the diagnosis which can be fatal to the patient outcomes. On the other hand, false positives were 436 cases where benign patches were mis-classified to be IDC. False positives could lead to unnecessary further tests and anxiety whereas the model has a relatively low false positive rate when compared to most of the currently available modalities. True negatives, non-cancerous patches that were rightly selected were 7,223 which is a good sign of the power of the model to rule out the non-cancerous ones. The confusion matrix demonstrates the impressive quantitative values noted with an accuracy of 90.76, good 93.56 F1-score indicating the equal performance of the accuracy and recall. The model is useful in resolving the inherent class imbalance always encountered in medical imaging datasets particularly in instances of IDC where positives are typically at a disadvantage. The balance is required to make the model clinically useful since this ensures that the number of missed malignancies (false negative) and unnecessary follow-up (false positive) are minimal. Its strong recall (sensitivity) = 91.2% reveals that the model is sound and can be used to detect most of the actual cancer cases, which is vital to intervene and lead to better prognoses at a less advanced stage. Meanwhile, the 92.8% accuracy of the positive prediction would confirm that most of the positive predictions are true which will reduce the expenses and psychological burden of false alarms.



Figure 2: Confusion matrix for TransResCNN

The bar chart visually summarizes the strong performance metrics achieved by the TransResCNN model in breast cancer detection, highlighting its balanced and robust classification capability. Accuracy and F1-score are among the highest indicators, with values of 90.76% and 93.56% respectively, demonstrating that the model effectively classifies both IDC-positive and IDC-negative cases while maintaining a balance between precision and recall. Precision at 92.8% reflects a low false positive rate, indicating the model's ability to minimize unnecessary follow-ups and anxiety caused by misclassifying benign tissue as malignant. Similarly, recall (or sensitivity) of 91.2% underscores the model's strength in correctly identifying the majority of true cancer cases, a critical feature for early diagnosis and improved patient outcomes. The ROC-AUC score of 0.94, presented as a percentage on the chart for comparison, further confirms the model's excellent discriminative power across different classification thresholds. Collectively, these metrics validate that TransResCNN outperforms many traditional convolutional neural networks as well as baseline models by addressing key challenges such as imbalanced datasets and subtle pathological variations in mammographic images. This visualization helps to quickly convey the model's clinical utility, emphasizing that it achieves high sensitivity and precision simultaneously—a necessary trait for diagnostic tools in oncology, where both missed diagnoses and false alarms carry significant clinical consequences. Ultimately, the chart encapsulates the model's capacity to improve breast cancer screening accuracy, supporting its potential for integration into real-world clinical workflows to enhance patient care.



Figure 3: Performance Metrics of TransResCNN Model

As can be seen in the plot of the ROC of the TransResCNN model, the model is highly able to separate IDC-positive and IDC-negative cases. The sharp curve with the large growth to the upper-left side signifies high true positive rates (sensitivity) at low false positive rates, which is the most valuable in clinical diagnostics to minimize false negativity of the cancer diagnosis, but not to induce false interventions. This high discriminative capacity is quantitatively validated by the ROC-AUC of 0.94 in the legend of this curve that the given model can distinguish between the malignant and benign image patches with 94 percent certainty. It is a field or a location that may be considered as a high-performing area in medical image analysis, where the diversity of tissue morphology and imbalance of the information may pose a challenge to the performance. The findings of this ROC analysis substantiate and support the results of this confusion matrix and other metrics findings, and can be used to further substantiate that the designed hybrid transfer learning and residual network architecture is effective in identifying significant histopathological features of breast cancer. Good clinical signs in ROC-AUC indicate that there are high diagnostic confidence and strength across different levels of decision thresholds that are flexible to clinical risks tolerance. The model is visually emphasized by the analogy of a guess on a coin i.e., the diagonal line of the baseline. Overall, the explanation of the ROC curve shows the promise of TransResCNN as a powerful AI tool that could be utilized to assist radiologists' decision-making and detect breast cancer at an early and precise stage.



Figure 4: ROC Curve for TransResCNN Breast Cancer Detection

Comparison with Baseline CNN Models

Figure 5 can be used to present a more in-depth comparison of five key deep-learning models VGG16, InceptionNet, DenseNet121, MobileNetV2, and the proposed TransResCNN, with the key performance rates of accuracy, precision, recall, F1-score, and ROC-AUC. According to the chart, TransResCNN is most faithful when comparing the results using all metrics, as it ranks better than the other two models that are not robust with respect to identifying invasive ductal carcinoma (IDC) in the histopathology images of the breast. Specifically, TransResCNN achieves an accuracy of 90.76, compared to 89.1 of DenseNet121, and other competitive methods. Its balance in identifying true positives correctly and minimizing false positives (92.8 and 91.2, respectively) is very high, which is vital in clinical reliability. By the better F1-score (93.56) there is a balanced trade-off between precision and recall, implying that fewer of the cases are misrepresented. Also, a ROC-AUC score of 0.94 indicates that the model is highly discriminative at various levels of classification compared to the baseline architectures that have the maximum classification threshold of 0.92. Such strong performance overall can be corroborated by a combination of transfer learning and the residual convolutional network architecture of the TransResCNN that enhances the depth of feature extraction as well as minimizes the vanishing gradients. On the other hand, these efficiency-oriented models (including MobileNetV2 and others) are not focused on peak performance, which explains the reduced scores. The relative visualization underpins the future clinical application of TransResCNN that will work more efficiently in identifying tumors, removing diagnostic errors, and, in turn, positively affecting the eventual outcome of breast cancer screening. It also promotes further studies on hybrid designs which rely on existing backbones with further enhancements that are applicable in the medical imaging challenges. On the whole, the bar chart graphically attests to the visual argument that TransResCNN is a step forward in the state-of-the-art in automated breast cancer detection.



Figure 5: Performance Comparison of Breast Cancer Detection Models

The model has performed optimally on the values of highest accuracy (90.76%), precision (92.8%), recall (91.2%), F1-score (93.56%), and ROC-AUC (0.94) in comparison to the other models such as well-established CNN backbones, including VGG16 (accuracy 87.2%), InceptionNet (88.4%), DenseNet121 (89.1%), and MobileNetV2 (86.8% Contrary to This accuracy versus recollection trade-off introduced by the high F1-value is very critical in a clinical arena where the primary aim of reducing false negatives to avoid undiagnosed cancers and false positives to avoid unnecessary biopsies takes precedence. The confusion matrix, the ROC curve, and the overall measures comparisons all confirm the high degree of the discriminative power and generalization of TransResCNN to the testing data. It signifies the interest in the model training techniques that incorporate data augmentation to address the problem of class imbalance,
hyperparameters optimization, and premature termination to overcome overfitting. Also, the results of TransResCNN compared to lightweight models like MobileNetV2 with an emphasis on efficiency, premised on the adoption of resource-constrained settings, demonstrate the importance of the complexity of the architectures to achieve diagnostic accuracy. The study findings add to the growing body of literature that hybrid deep learning models featuring transfer learning capabilities outperform directly learned models, especially in the field of medical imaging where annotated data are usually limited. Clinically, such AI tools should reduce the workload of radiologists, improve screening throughput and ultimately increase patient prognosis through early and more proactive

diagnosis. Though these positive results were obtained, some other weaknesses like the variability of the data source and the mechanisms to ensure clinical trust are also addressed. Future studies can consider multimodal image combining, federated training which would train models privately across institutions and lightweight versions of models to apply the benefits globally. With that said, the study offers a powerful indication that the development of advanced AI algorithms like TransResCNN in cancer of the breast are indeed possible, and it is a big step in the way of AI-enriching diagnostic procedures that would transform the practice of early cancer detection.

Conclusion and Future Work

The study ends with the recommendation that TransResCNN is the most suitable deep learning model to bring about a high-performance in invasive ductal carcinoma (i.e. automated breast cancer detection) using mammographic histopathological images through the incorporation of transfer learning, and residual convolutional neural networks to the deep learning model. The model has high accuracy (90.76%), precision (92.8%), recall (91.2%), F1-score (93.56%) and ROC-AUC (0.94), indicating its robustness and clinical use in reducing the diagnostic error rate and supporting the early detection of cancer. All these achievements demonstrate that the model can resolve issues of class imbalance, subtle tissue heterogeneity, and complex imaging patterns in a much better way compared to the default CNN structures including VGG16 and DenseNet121. Notably, the proposed solution can assist radiologists to obtain plausible second opinions, enhance the degree of diagnostic certainty, and, potentially, patient outcomes because of the capacity to act in time.

To proceed with the work on the project, it is proposed that certain promising directions are to be adopted so that TransResCNN can become even more relevant to clinical practice and scalable. The data generalization and reduction of bias would be better achieved by generalizing the models using more institutions and multi-ethnic groups to the data. Additionally, more explainable AI approaches, such as saliency maps or SHAP values, can as well be taken into consideration, and predictions of the model can be made more interpretable so that clinicians can more easily interpret these models and apply them in practice. The future of data fusion in multimodal data of ultrasound, MRI and clinical metadata may provide a more holistic perspective of the diagnostic opinion. The other significant way ahead is to develop additional light and edge friendly models in order to be able to implement it in resource constrained settings and also be in a position to have real time clinical decision support. Additionally, federated learning may ensure that the privacy-saving training at numerous healthcare facilities can be guaranteed, and that will remove regulatory and ethical concerns. Finally, the model could also be used in other ways that we could not detect in terms of prognostic assessment and response to treatment by expansion. The research establishes a strong foundation of these developments whose aim is to translate AI advancements into feasible clinical uses, which can improve global treatment of breast cancer.

REFERENCES

[1] A. L. Hilliard, T. D. Russell, P. Mendonca, and K. F. A. Soliman, "Targeting the Tumor Immune Microenvironment in Triple-Negative Breast Cancer: The Promise of Polyphenols," *Cancers (Basel)*, vol. 17, no. 17, p. 2794, 2025, doi: 10.3390/cancers17172794.

[2] M. A. Tariq, W. Akbar, S. A. Batool, M. K. Abid, and N. Aslam, "Breast Cancer Detection Using Deep Learning Algorithms," *Journal of Computing & Biomedical Informatics*, 2024.

[3] P. J. Sudharshan, C. Petitjean, F. Spanhol, L. E. Oliveira, L. Heutte, and P. Honeine, "Multiple instance learning for histopathological breast cancer image classification," *Expert Syst Appl*, vol. 117, pp. 103–111, 2019, doi: 10.1016/j.eswa.2018.09.049.

[4] W. Arshad, T. Masood, H. M. Shahzad, H. A. Ahmed, S. H. Ahmed, and H. M. T. Khushi, "HistoDX: Revolutionizing Breast Cancer Diagnosis Through Advanced Imaging Techniques," *IEEE Access*, 2025.

[5] M. A. M. I. Hamid Ghous Mubasher Malik, "Early Detection of Breast Cancer Tumors Using Linear Discriminant Analysis Feature Selection with Different Classification Methods," *International Journal of Information Systems and Computer Technologies*, vol. 1, no. 1, 2022, doi: 10.58325/ijisct.001.01.0008.

[6] U. B. Ansari and T. Sarode, "Skin cancer detection using image processing," *Int Res J Eng Technol*, vol. 4, no. 4, pp. 2875–2881, 2017.

[7] M. Ali Tariq, W. Akbar, S. Ali Batool, M. Kamran Abid, N. Aslam, and S. Qadri, "Breast Cancer Detection Using Deep Learning Algorithms," 2024.

[8] D. Joseph, A. Paul, T. Abinaya, V. Anand, and P. Pandian, "Optimal deep learning model for skin cancer detection," *Multimed Tools Appl*, vol. 80, no. 23, pp. 35121–35140, 2021.

[9] R. Idrees *et al.*, "Lung cancer detection using supervised machine learning techniques," 2022.

[10] S. S. Mane and S. V Shinde, "Different techniques for skin cancer detection using dermoscopy images," *Int J Comput Sci Eng*, vol. 5, no. 12, pp. 165–170, 2017.

[11] S. S. Mane and S. V Shinde, "Different techniques for skin cancer detection using dermoscopy images," *Int J Comput Sci Eng*, vol. 5, no. 12, pp. 165–170, 2017.

[12] S. Iqbal *et al.*, "Prostate cancer detection using deep learning and traditional techniques," *IEEE Access*, vol. 8, no. 9, pp. 27085–27100, 2021.

[13] M. Dildar *et al.*, "Skin cancer detection: a review using deep learning techniques," *Int J Environ Res Public Health*, vol. 18, no. 11, p. 5799, 2021.

[14] A. Hekler *et al.*, "Superior skin cancer classification by the combination of human and artificial intelligence," *Eur J Cancer*, vol. 120, pp. 114–121, 2019.

[15] M. M. Vijayalakshmi, "Melanoma skin cancer detection using image processing and machine learning," *Int J Trend Sci Res Dev*, vol. 3, no. 4, pp. 780–784, 2019.

[16] G. Franceschini and L. Liu, "Performance comparison of deep learning models for skin cancer detection," *IEEE Access*, vol. 10, pp. 127567–127580, 2022.

[17] R. Parveen, U. Saleem, K. Abid, and N. Aslam, "Identification of Lungs Cancer by using Watershed Machine Learning Algorithm," *VFAST Transactions on Software Engineering*, vol. 11, no. 2, pp. 70–79, 2023.

[18] S. M. Ayyad, A. I. Saleh, and L. M. Labib, "Gene expression cancer classification using modified K-Nearest Neighbors technique," *BioSystems*, vol. 176, no. July 2018, pp. 41–51, 2019, doi: 10.1016/j.biosystems.2018.12.009.

[19] S. Jain, U. Singhania, B. Tripathy, E. A. Nasr, M. K. Aboudaif, and A. K. Kamrani, "Deep learning-based transfer learning for classification of skin cancer," *Sensors*, vol. 21, no. 23, p. 8142, 2021.

[20] S. Jain, U. Singhania, B. Tripathy, E. A. Nasr, M. K. Aboudaif, and A. K. Kamrani, "Deep learning-based transfer learning for classification of skin cancer," *Sensors*, vol. 21, no. 23, p. 8142, 2021.

[21] K. Khaliq, A. Naeem, N. Aslam, A. Malik, and K. Abid, "LCCNet: a deep learning based Method for the identification of lungs Cancer using CT scans," *VFAST Transactions on Software Engineering*, vol. 11, no. 2, pp. 80–93, 2023.

[22] M. A. K. Muhammad Kamran Abid Mubshra qadir Mujahid Alam, "Using Deep Learning for pneumonia Recognition from Chest X-Ray Images," *Technical Journal*, vol. 29, no. 02, 2024.

[23] A. Naeem, A. H. Khan, S. u din Ayubi, and H. Malik, "Predicting the Metastasis Ability of Prostate Cancer using Machine Learning Classifiers," *Journal of Computing & Biomedical Informatics*, vol. 4, no. 02, pp. 1–7, 2023.

[24] A. Kanwal, K. T. Ahmad, N. Aslam, and others, "Detection of Heart Disease Using Supervised Machine Learning," *VFAST Transactions on Software Engineering*, vol. 10, no. 3, pp. 58–70, 2022.

[25] S. Ali Batool, M. Ali Tariq, A. Ali Batool, M. Kamran Abid, and N. Aslam, "Skin Cancer Detection Using Deep Learning Algorithms", doi: 10.56979/701/2024.

[26] U. Reddy, B. Reddy, and B. Reddy, "Recognition of lung cancer using machine learning mechanisms with fuzzy neural networks," *Traitement du Signal*, vol. 36, no. 1, pp. 87–91, 2019.

[27] R. Narayan and Y. Patel, "Deep learning and its application in skin cancer diagnosis: A systematic review," *Artif Intell Med*, vol. 129, p. 102318, 2022.